GVV858
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
May 25, 2026
CGVV858A12101: Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors
(clinicaltrialsregister.eu)
- P1/2 | N=55 | Not yet recruiting | Sponsor: Novartis Pharma AG
New P1/2 trial • Breast Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • HER-2
May 18, 2026
CGVV858A12101: Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors
(clinicaltrialsregister.eu)
- P1/2 | N=55 | Not yet recruiting | Sponsor: Novartis Pharma AG | N=26 ➔ 55
Enrollment change • Breast Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • HER-2
April 20, 2026
CGVV858A12101: Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors
(clinicaltrialsregister.eu)
- P1/2 | N=26 | Not yet recruiting | Sponsor: Novartis Pharma AG
New P1/2 trial • Breast Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • HER-2
December 23, 2025
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=205 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Breast Cancer • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Prostate Cancer • Solid Tumor
December 18, 2025
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=205 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals
New P1/2 trial • Breast Cancer • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Prostate Cancer • Solid Tumor
1 to 5
Of
5
Go to page
1